Policy guide

Can you advertise research peptides on Facebook?

Updated August 2026·10 min read

The short answer

Yes, but conditionally, and the conditions are stricter than most people selling in this category realise. Research-use-only compounds are not on Meta’s outright prohibited list the way recreational drugs are. They sit in a grey zone governed by several overlapping policies, and whether you last depends almost entirely on how you describe what you sell.

The advertisers who get pulled in a week and the ones who run for years are usually selling near-identical products. The difference is language and infrastructure, not luck.

Which policies actually apply

People look for a “peptide policy.” There isn’t one. Enforcement in this category comes from four separate policies stacking:

• Unsafe Substances. Aimed at unsafe supplements and unapproved compounds. Human-use framing pulls you squarely into it.
• Personal Health and Appearance. The one that catches body-outcome claims. It restricts ads implying negative self-perception or promising physical change — weight, fat, muscle, body composition.
• Unacceptable Business Practices. The catch-all for misleading claims, and the label you most often see on a disabled account notice even when the real trigger was elsewhere.
• Prescription Drugs. Triggered by medical and clinical framing — “pharmaceutical grade,” “doctor recommended,” “therapy,” “patients.”

You can trip any one of these without touching the others, which is why advertisers often fix the obvious problem and get pulled again for something they never considered.

Where the line sits

The workable distinction is straightforward once you see it: describe the material, not the effect on a person.

Claims that generally survive review:

• Purity and testing — HPLC verified, mass spec confirmed, third-party tested, certificate of analysis available per batch
• Research-use framing stated plainly and consistently
• Operational facts — shipping speed, tracking, cold-chain handling, batch numbering
• Compound identity and specification — what it is, at what purity, in what quantity

Claims that reliably cause problems:

• Anything implying a human takes it — dosage, administration, “safe for human use”
• Body outcomes — weight loss, fat loss, lean muscle, sculpting, transformation
• Efficacy claims — “clinically proven,” “guaranteed results,” anything with cure/treat/heal
• Testimonials and before-and-afters, including customer reviews on the page
• Medical framing — pharmaceutical grade, clinical use, doctor recommended
• Evasion signals — “discreet,” “no questions asked,” “under the radar”

You can run your own copy through our free claim checker to see which of these it trips.

Your landing page is part of the ad

This is the single most expensive misunderstanding in the category. Reviewers do not evaluate the ad in isolation. They open the destination, read the product page, read the collection page above it, and read the reviews. All of it is treated as your advertising claim.

A perfectly compliant ad pointing at a product page with transformation photos in the reviews will fail, and the disapproval will name the ad. People then rewrite the ad, resubmit, fail again, and conclude enforcement is random.

The most common miss is the collection or category page — often built early, rarely revisited, and frequently carrying exactly the outcome language the product pages had scrubbed years ago.

Why verification changes what you can do

Business verification and domain verification do not exempt you from the category. What they do is change how the account is treated: default spend limits are higher, review friction is lower, appeals are handled differently, and certain features simply are not available to unverified businesses.

In a restricted category, that difference compounds. An unverified account carrying a borderline claim is treated very differently from a verified one carrying the same claim. It is the least glamorous work available and it has more effect on durability than creative does.

What separates advertisers who last

Four things, consistently:

• Consistent research framing everywhere. Ads, product pages, collections, email, reviews, packaging. Consistency is what a reviewer is actually checking.
• Verified, matching infrastructure. Entity, domain, descriptor and site all agreeing with each other.
• Separated properties. Multiple compliant accounts and domains, so one restriction is a dip rather than an outage.
• Monitoring. Enforcement starts with a single disapproval or a quiet delivery drop, days before a ban. Catching that on the day is the difference between an adjustment and a rebuild.

None of this is exotic. It is unglamorous discipline, applied consistently, in a category that punishes shortcuts harder than most.